5 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Targeting novel lipid pathways for treatment of cardiovascular disease (Athero-Flux)
Date du début: 1 sept. 2013, Date de fin: 31 août 2018,
Lipid lowering has significantly reduced cardiovascular disease (CVD) mortality in EU. However, the aim to abolish CVD in EU is far from achieved and attempts to improve on the benefits of statins with new agents have not yet delivered new therapeutics. The Consortium Athero-Flux builds on FP7-generated large-scale lipidomics data showing that specific sphingolipids and in particular distinct cer ...
Voir le projet
12
Participants partenaires
TERMINÉ
Micropattern-Enhanced High Throughput RNA Interference for Cell Screening (MEHTRICS)
Date du début: 1 oct. 2011, Date de fin: 31 janv. 2015,
...ce for all major applications of HT/HC cell screening. The resulting new tools and methodologies will be incorporated into the commercial offerings of the consortium’s two key SMEs, CYTOO and CENIX.
Voir le projet
6
Participants partenaires
TERMINÉ
Targeted Amphoteric Carriers in ImmunoTherapy (TACIT)
Date du début: 1 août 2009, Date de fin: 31 juil. 2013,
"The past year has been exciting for oligonucleotide-based drug discovery and development. The Nobel Prize was awarded to Mello and Fire for discovering RNA interference. There was also big investment from the Pharmaceutical industry to Biotechnology companies-pioneers in oligonucleotide therapeutics such as Sirna, Alnylam and Isis, all US-based. High expectations were therefore raised but further ...
Voir le projet
4
Participants partenaires
TERMINÉ
Multi-layer network modules to identify markers for personalized medication in complex diseases (MultiMod)
Date du début: 1 nov. 2008, Date de fin: 31 oct. 2012,
The symptoms of complex disease like allergy, obesity and cancer depend on the products of multiple interacting genes. High-throughput techniques have implicated hundreds of genes. There are also considerable individual variations. A clinical implication of this may be inadequate treatment response, which is increasingly recognized as a cause of increased suffering and costs. Ideally, physicians s ...
Voir le projet
6
Participants partenaires
TERMINÉ
An urgent need exists for more specific treatment options to target the metabolic changes and the related inflammatory pathways during HF. Targeting microRNAs (miRNAs)-small RNAs implicated in protein regulation- represents a unique possibility to make novel medicines against HF. In view of the central role of inflammatory pathways in the metabolic syndrome, they expect inflammation miRNAs to be e ...
Voir le projet